

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Hong Kong Securities Clearing Company Limited (“**HKSCC**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not, and is not intended to, constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States or in any other jurisdiction. The Offer Shares have not been and will not be registered under the United States Securities Act of 1933, as amended from time to time (the “**U.S. Securities Act**”) or securities law of any state or other jurisdiction of the United States and may not be offered, sold, pledged or otherwise transferred within the United States, except in transactions exempt from, or not subject to, the registration requirements of the U.S. Securities Act and in compliance with any applicable state securities laws. There will be no public offer of the Offer Shares in the United States. The Offer Shares are being offered and sold solely outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act and applicable laws of each jurisdiction where those offers and sales occur. This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities.

This announcement is not a prospectus. Potential investors should read the prospectus dated October 28, 2025 (the “**Prospectus**”) issued by Vigonvita Life Sciences Co., Ltd. (蘇州旺山旺水生物醫藥股份有限公司) (the “**Company**”) for detailed information about the Global Offering described below before deciding whether or not to invest in the H Shares thereby being offered. The Company has not been and will not be registered under the U.S. Investment Company Act of 1940, as amended.

Unless otherwise defined in this announcement, capitalized terms used herein shall have the same meanings as those defined in the Prospectus.

In connection with the Global Offering, CLSA Limited as the stabilizing manager (the “**Stabilizing Manager**”) or any person acting for it may make purchases, over-allocate or effect transactions in the market or otherwise take such stabilizing action(s) with a view to stabilizing or supporting the market price of the H Shares at a level higher than that which might otherwise prevail for a limited period after the Listing Date. Any such stabilizing action will be effected in compliance with all applicable laws and regulatory requirements, including the Securities and Futures (Price Stabilizing) Rules under the SFO. However, there is no obligation on the Stabilizing Manager or any person acting for it to conduct any such stabilizing action. Such stabilizing action, if taken, (a) will be conducted at the absolute discretion of the Stabilizing Manager or any person acting for it, (b) may be discontinued at any time and (c) is required to be brought to an end within 30 days after the last day for lodging applications under the Hong Kong Public Offering.

Potential investors should note that no stabilizing action can be taken to support the price of the H Shares for longer than the stabilization period, which will begin on the Listing Date and is expected to expire on December 3, 2025, being the 30th day after the last day for lodging applications under the Hong Kong Public Offering. After this date, when no further stabilizing action may be taken, demand for the H Shares, and therefore the price of the H Shares, could fall.

The obligations of the Hong Kong Underwriters under the Hong Kong Underwriting Agreement to procure subscribers for, or themselves to subscribe for, the Hong Kong Offer Shares, are subject to termination by the Sole Sponsor and the Sponsor-Overall Coordinator (for itself and on behalf of the Hong Kong Underwriters) if certain grounds arise prior to 8:00 a.m. on the Listing Date. Such grounds are set out in the section headed “Underwriting — Underwriting Arrangements and Expenses — Hong Kong Public Offering — Grounds for Termination” in the Prospectus. It is important that you refer to that section for further details.



**Vigonvita Life Sciences Co., Ltd.**

**蘇州旺山旺水生物醫藥股份有限公司**

*(a joint stock company incorporated in the People's Republic of China with limited liability)*

**GLOBAL OFFERING**

<b>Number of Offer Shares in the Global Offering</b>	<b>: 17,597,800 H Shares (subject to the Over-allotment Option)</b>
<b>Number of Hong Kong Offer Shares</b>	<b>: 1,759,800 H Shares</b>
<b>Number of International Offer Shares</b>	<b>: 15,838,000 H Shares (subject to the Over-allotment Option)</b>
<b>Final Offer Price</b>	<b>: HK\$33.37 per H Share, plus brokerage of 1.0%, SFC transaction levy of 0.0027%, AFRC transaction levy of 0.00015% and Stock Exchange trading fee of 0.00565%</b>
<b>Nominal Value</b>	<b>: RMB1.00 per H Share</b>
<b>Stock Code</b>	<b>: 2630</b>

***Sole Sponsor, Sponsor-Overall Coordinator, Overall Coordinator, Joint Global Coordinator, Joint Bookrunner and Joint Lead Manager***



**CITIC SECURITIES**

***Overall Coordinators, Joint Global Coordinators, Joint Bookrunners and Joint Lead Managers***



**CICC 中金公司**



**ABCI 農銀國際**



**中國銀河國際  
CHINA GALAXY INTERNATIONAL**

***Joint Bookrunners and Joint Lead Managers (in alphabetical order)***




**建銀國際  
CIB International**



**光大證券 國際  
EVERBRIGHT SECURITIES INTERNATIONAL**



**富途證券  
FUTU Securities International**



**老虎證券**



**ZTSC 中泰國際**

**VIGONVITA LIFE SCIENCES CO., LTD./**  
**蘇州旺山旺水生物醫藥股份有限公司**  
**ANNOUNCEMENT OF FINAL OFFER PRICE AND**  
**ALLOTMENT RESULTS**

*Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings as those defined in the prospectus dated October 28, 2025 (the “**Prospectus**”) issued by Vigonvita Life Sciences Co., Ltd. (the “**Company**”).*

**Warning: In view of high concentration of shareholding in a small number of H Shareholders, H Shareholders and prospective investors should be aware that the price of the H Shares could move substantially even with a small number of H Shares traded and should exercise extreme caution when dealing in the H Shares.**

**SUMMARY**

Company information	
Stock code	2630
Stock short name	VIGONVITA-B
Dealings commencement date	November 6, 2025*

\* see note at the end of the announcement

Price Information	
Final Offer Price	HK\$33.370
Offer Price Range	HK\$32.000 – HK\$34.000

Offer Shares and Share Capital	
Number of Offer Shares	17,597,800
Final Number of Offer Shares in Hong Kong Public Offering	1,759,800
Final Number of Offer Shares in International Offering	15,838,000
Number of issued shares upon Listing	167,597,800

Proceeds	
<b>Gross proceeds (Note)</b>	HK\$587.24 million
<b>Less: Estimated listing expenses payable based on final Offer Price</b>	HK\$(59.88) million
<b>Net proceeds</b>	HK\$527.36 million
<b>Number of Offer Shares under Hong Kong Public Offering</b>	1,759,800
<b>Number of Offer Shares under International Offering</b>	15,838,000

*Note: Gross proceeds refers to the amount to which the issuer is entitled receive. For details of the use of proceeds, please refer to the Prospectus dated October 28, 2025.*

## ALLOTMENT RESULTS DETAILS

### HONG KONG PUBLIC OFFERING

<b>No. of valid applications</b>	265,188
<b>No. of successful applications</b>	8,799
<b>Subscription level</b>	6,238.42 times
<b>Claw-back triggered</b>	No
<b>No. of Offer Shares initially available under the Hong Kong Public Offering</b>	1,759,800
<b>Final no. of Offer Shares under the Hong Kong Public Offering</b>	1,759,800
<b>% of Offer Shares under the Hong Kong Public Offering to the Global Offering</b>	10.00%

*Note: For details of the final allocation of shares to the Hong Kong Public Offering, investors can refer to <https://www.eipo.com.hk/eIPOAllotment> to perform a search by identification number or <https://www.eipo.com.hk/eIPOAllotment> for the full list of allottees.*

## INTERNATIONAL OFFERING

<b>No. of placees</b>	70
<b>Subscription Level</b>	16.87 times
<b>No. of Offer Shares initially available under the International Offering</b>	15,838,000
<b>Final no. of Offer Shares under the International Offering</b>	15,838,000
<b>% of Offer Shares under the International Offering to the Global Offering</b>	90.00%

*The Directors confirm that, to the best of their knowledge, information and belief, (i) none of the Offer Shares subscribed by the placees and the public have been financed directly or indirectly by the Company, any of the Directors, chief executive of the Company, Controlling Shareholders, substantial shareholders, existing Shareholders of the Company or any of its subsidiaries or their respective close associates; and (ii) none of the placees and the public who have purchased the Offer Shares are accustomed to taking instructions from the Company, any of the Directors, chief executive of the Company, Controlling Shareholders, substantial shareholders, existing Shareholders of the Company or any of its subsidiaries or their respective close associates in relation to the acquisition, disposal, voting or other disposition of Shares registered in his/her/its name or otherwise held by him/her/it.*

### **Allottee with consent obtained**

<i>Investor</i>	<i>No. of shares allocated</i>	<i>% of offer shares</i>	<i>% of total issued H Shares after the Global Offering</i>	<i>% of total issued share capital after the Global Offering</i>	<i>Relationship*</i>
CITIC Securities International Capital Management Limited	3,600	0.02%	0.01%	0.00%	Connected client
Total	3,600	0.02%	0.01%	0.00%	

\* *The H Shares placed to the above allottee are held on behalf of independent third parties (as defined in Chapter 4.15 of the Guide for New Listing Applicants) and are in compliance with all the conditions under the consent granted by the Stock Exchange.*

## ***LOCK-UP UNDERTAKINGS***

### ***Controlling Shareholders***

<i>Name</i>	<i>Number of shares held in the Company subject to lock-up undertakings upon listing</i>	<i>Number of H Shares held in the Company subject to lock-up undertakings upon listing</i>	<i>% of total issued H Shares after the Global Offering subject to lock-up undertakings upon listing</i>	<i>% of shareholding in the Company subject to lock-up undertakings upon listing (assuming the Over-allotment Option is not exercised)</i>	<i>Last day subject to the lock-up undertakings</i>
Dr. Shen Jingshan/ 沈敬山	82,461,110	0	0.00%	49.20%	November 5, 2026
Ms. Jin Jie/金潔	2,272,478	0	0.00%	1.36%	November 5, 2026
Subtotal	84,733,588	0	0.00%	50.56%	
<i>Pursuant to applicable PRC laws, all existing Shareholders could not dispose of any of the Shares held by them within 12 months from the Listing Date. The lock-up requirement under PRC laws is longer than the lock-up period required of Controlling Shareholders under Rule 10.07 of the Listing Rules.</i>					

***Existing Shareholders (including the Pre-IPO Investors as defined in the “History, Development and Corporate Structure” section of the Prospectus)***

<i>Name</i>	<i>Number of shares held in the Company subject to lock-up undertakings upon listing</i>	<i>Number of H Shares held in the Company subject to lock-up undertakings upon listing</i>	<i>% of total issued H Shares after the Global Offering subject to lock-up undertakings upon listing</i>	<i>% of shareholding in the Company subject to lock-up undertakings upon listing (assuming the Over-allotment Option is not exercised)</i>	<i>Last day subject to the lock-up undertakings</i>
Dr. Tian Guanghui/田廣輝	14,316,611	8,589,967	12.88%	8.54%	November 5, 2026
Ganzhou Yufei Shanshui Equity Investment Partnership Enterprise (Limited Partnership)/贛州予飛杉水股權投資合夥企業(有限合夥)	7,174,758	3,000,000	4.50%	4.28%	November 5, 2026
Suzhou Hesheng Enterprise Management Consulting Partnership Enterprise (Limited Partnership)/蘇州合升企業管理諮詢合夥企業(有限合夥)	6,783,346	6,783,346	10.17%	4.05%	November 5, 2026
Ms. Jin Qing/金青	5,517,145	5,517,145	8.27%	3.29%	November 5, 2026
Gongqingcheng Zhongcai Qihu Financial Control Phase II Internet Industry Investment Center (Limited Partnership)/共青城中財奇虎金控二期互聯網產業投資中心(有限合夥)	4,370,157	4,370,157	6.55%	2.61%	November 5, 2026
Suzhou Xieyao Kexin Venture Capital Partnership Enterprise (Limited Partnership)/蘇州協耀科新創業投資合夥企業(有限合夥)	4,370,157	4,370,157	6.55%	2.61%	November 5, 2026
Suzhou Xieyao Kesheng Entrepreneurship Investment Partnership Enterprise (Limited Partnership)/蘇州協耀科盛創業投資合夥企業(有限合夥)	1,032,546	1,032,546	1.55%	0.62%	November 5, 2026
Suzhou Meilingge Business Consulting Partnership Enterprise (Limited Partnership)/蘇州美靈格商務諮詢合夥企業(有限合夥)	1,092,539	1,092,539	1.64%	0.65%	November 5, 2026

<i>Name</i>	<i>Number of shares held in the Company subject to lock-up undertakings upon listing</i>	<i>Number of H Shares held in the Company subject to lock-up undertakings upon listing</i>	<i>% of total issued H Shares after the Global Offering subject to lock-up undertakings upon listing</i>	<i>% of shareholding in the Company subject to lock-up undertakings upon listing (assuming the Over-allotment Option is not exercised)</i>	<i>Last day subject to the lock-up undertakings</i>
Jiaxing Yuhan Equity Investment Partnership Enterprise (Limited Partnership)/嘉興譽瀚股權投資合夥企業(有限合夥)	3,763,519	2,763,519	4.14%	2.25%	November 5, 2026
Qingdao Bei'an Industrial Investment Holding Co., Ltd./青島北岸產業投資控股有限公司	3,401,354	0	0.00%	2.03%	November 5, 2026
Shenzhen Ruikang Yuhong Win Win Investment Partnership (Limited Partnership)/深圳市銳康宇宏共贏投資合夥企業(有限合夥)	1,929,197	1,429,197	2.14%	1.15%	November 5, 2026
Hainan Junshi Phase I Equity Investment Fund Partnership Enterprise (Limited Partnership)/海南君實一期股權投資基金合夥企業(有限合夥)	1,720,925	1,720,925	2.58%	1.03%	November 5, 2026
Hangzhou Hemeng Medical Intelligence Equity Investment Partnership Enterprise (Limited Partnership)/杭州和盟醫智股權投資合夥企業(有限合夥)	1,376,758	1,376,758	2.06%	0.82%	November 5, 2026
Qingdao Wangde Venture Capital Partnership Enterprise (Limited Partnership)/青島旺德創業投資合夥企業(有限合夥)	1,241,500	1,241,500	1.86%	0.74%	November 5, 2026
Fuzhou Yide Equity Investment Partnership Enterprise (Limited Partnership)/福州宜德股權投資合夥企業(有限合夥)	1,032,546	1,032,546	1.55%	0.62%	November 5, 2026
Suzhou Junding Changwang Entrepreneurship Investment Center (Limited Partnership)/蘇州君鼎長旺創業投資中心(有限合夥)	1,032,546	1,032,546	1.55%	0.62%	November 5, 2026



<i>Name</i>	<i>Number of shares held in the Company subject to lock-up undertakings upon listing</i>	<i>Number of H Shares held in the Company subject to lock-up undertakings upon listing</i>	<i>% of total issued H Shares after the Global Offering subject to lock-up undertakings upon listing</i>	<i>% of shareholding in the Company subject to lock-up undertakings upon listing (assuming the Over-allotment Option is not exercised)</i>	<i>Last day subject to the lock-up undertakings</i>
Suzhou Industrial Investment Innovation and Entrepreneurship Investment Partnership Enterprise (Limited Partnership)/蘇州產投創新創業投資合夥企業(有限合夥)	876,904	876,904	1.32%	0.52%	November 5, 2026
Hubei Jiuzhou Ketou Health Venture Capital Fund Partnership (Limited Partnership)/湖北九州科投健康創業投資基金合夥企業(有限合夥)	869,116	869,116	1.30%	0.52%	November 5, 2026
Fuzhou Xindui Investment Partnership Enterprise (Limited Partnership)/福州鑫兌投資合夥企業(有限合夥)	688,379	0	0.00%	0.41%	November 5, 2026
Dr. Hu Tianwen/胡天文	681,743	681,743	1.02%	0.41%	November 5, 2026
Dr. Wang Zhiqiang/王志強	397,683	198,842	0.30%	0.24%	November 5, 2026
Ms. Guo Ting/郭婷	397,683	99,421	0.15%	0.24%	November 5, 2026
Ms. Yao Zheng/藥箏	397,683	198,842	0.30%	0.24%	November 5, 2026
Dr. Zheng Wei/鄭偉	340,872	340,872	0.51%	0.20%	November 5, 2026
Dr. Yang Rulei/楊汝磊	227,248	227,248	0.34%	0.14%	November 5, 2026
Mr. Li Jian/李建	170,436	170,436	0.26%	0.10%	November 5, 2026
Hubei Chuangxin Tongxiang Enterprise Management Partnership (Limited Partnership)/湖北創新同享企業管理合夥企業(有限合夥)	63,061	63,061	0.09%	0.04%	November 5, 2026
Subtotal	65,266,412	49,079,333	73.61%	38.94%	
<i>Pursuant to applicable PRC laws, all existing Shareholders could not dispose of any of the Shares held by them within 12 months from the Listing Date.</i>					

## **PLACEE CONCENTRATION ANALYSIS**

<b>Placees</b>	<b>Number of H Shares allotted</b>	<b>Allotment as % of International Offering (assuming no exercise of the Over-allotment Option)</b>	<b>Allotment as % of total Offer Shares (assuming no exercise of the Over-allotment Option)</b>	<b>Number of Shares held upon Listing</b>	<b>% of total issued share capital upon Listing (assuming no exercise of the Over-allotment Option)</b>
Top 1	1,869,800	11.81%	10.63%	1,869,800	1.12%
Top 5	7,674,800	48.46%	43.61%	7,674,800	4.58%
Top 10	12,288,800	77.59%	69.83%	12,288,800	7.33%
Top 25	15,800,800	99.77%	89.79%	15,800,800	9.43%

### *Notes*

\* *Ranking of placees is based on the number of H Shares allotted to the placees.*

## **H SHAREHOLDERS CONCENTRATION ANALYSIS**

<b>H Shareholders*</b>	<b>Number of H Shares allotted</b>	<b>Allotment as % of International Offering (assuming no exercise of the Over-allotment Option)</b>	<b>Allotment as % of total Offer Shares (assuming no exercise of the Over-allotment Option)</b>	<b>Number of H Shares held upon Listing</b>	<b>% of total issued H Shares capital upon Listing (assuming no exercise of the Over-allotment Option)</b>	<b>Number of Shares held upon Listing</b>
Top 1	0	0.00%	0.00%	8,589,967	12.88%	14,316,611
Top 5	0	0.00%	0.00%	31,755,857	47.63%	37,482,501
Top 10	1,869,800	11.81%	10.63%	43,384,147	65.07%	54,285,549
Top 25	12,288,800	77.59%	69.83%	60,069,411	90.09%	71,470,813

### *Notes*

\* *Ranking of H Shareholders is based on the number of H Shares held by the H Shareholders upon Listing.*

## **SHAREHOLDER CONCENTRATION ANALYSIS**

Shareholders	Number of H Shares allotted	Allotment as % of International Offering (assuming no exercise of the Over-allotment Option)	Allotment as % of total Offer Shares (assuming no exercise of the Over-allotment Option)	Number of H Shares held upon Listing	Number of Shares held upon Listing	% of total issued share capital upon Listing (assuming no exercise of the Over-allotment Option)
Top 1	0	0.00%	0.00%	0	84,733,588	50.56%
Top 5	0	0.00%	0.00%	24,868,555	119,503,545	71.30%
Top 10	0	0.00%	0.00%	39,793,422	138,829,766	82.84%
Top 25	11,535,800	72.84%	65.55%	58,634,668	158,171,012	94.38%

### *Notes*

\* *Ranking of Shareholders is based on the number of Shares (of all classes) held by the Shareholder upon Listing.*

## ***BASIS OF ALLOCATION UNDER THE HONG KONG PUBLIC OFFERING***

Subject to the satisfaction of the conditions set out in the Prospectus, valid applications made by the public will be conditionally allocated on the basis set out below:

<b>NO. OF SHARES APPLIED FOR</b>	<b>NO. OF VALID APPLICATIONS</b>	<b>BASIS OF ALLOTMENT/BALLOT</b>	<b>APPROXIMATE PERCENTAGE ALLOTTED OF THE TOTAL NO. OF SHARES APPLIED FOR</b>
<b>POOL A</b>			
200	117,011	1,960 out of 117,011 to receive 200 Shares	1.68%
400	19,752	331 out of 19,752 to receive 200 Shares	0.84%
600	18,808	316 out of 18,808 to receive 200 Shares	0.56%
800	4,282	72 out of 4,282 to receive 200 Shares	0.42%
1,000	4,930	83 out of 4,930 to receive 200 Shares	0.34%
1,200	2,051	35 out of 2,051 to receive 200 Shares	0.28%
1,400	9,331	160 out of 9,331 to receive 200 Shares	0.24%
1,600	1,837	32 out of 1,837 to receive 200 Shares	0.22%
1,800	1,196	21 out of 1,196 to receive 200 Shares	0.20%
2,000	9,181	162 out of 9,181 to receive 200 Shares	0.18%
3,000	4,976	88 out of 4,976 to receive 200 Shares	0.12%
4,000	3,125	56 out of 3,125 to receive 200 Shares	0.09%
5,000	2,378	43 out of 2,378 to receive 200 Shares	0.07%
6,000	2,123	39 out of 2,123 to receive 200 Shares	0.06%
7,000	1,350	25 out of 1,350 to receive 200 Shares	0.05%
8,000	1,497	28 out of 1,497 to receive 200 Shares	0.05%
9,000	1,217	23 out of 1,217 to receive 200 Shares	0.04%
10,000	5,247	100 out of 5,247 to receive 200 Shares	0.04%
15,000	3,741	72 out of 3,741 to receive 200 Shares	0.03%
20,000	3,521	68 out of 3,521 to receive 200 Shares	0.02%
25,000	2,413	47 out of 2,413 to receive 200 Shares	0.02%
30,000	2,573	52 out of 2,573 to receive 200 Shares	0.01%
35,000	1,552	32 out of 1,552 to receive 200 Shares	0.01%
40,000	1,768	37 out of 1,768 to receive 200 Shares	0.01%
45,000	1,232	28 out of 1,232 to receive 200 Shares	0.01%
50,000	1,912	44 out of 1,912 to receive 200 Shares	0.01%
60,000	1,931	45 out of 1,931 to receive 200 Shares	0.01%
70,000	1,391	33 out of 1,391 to receive 200 Shares	0.01%
80,000	1,559	39 out of 1,559 to receive 200 Shares	0.01%
90,000	1,230	32 out of 1,230 to receive 200 Shares	0.01%
100,000	2,090	55 out of 2,090 to receive 200 Shares	0.01%
120,000	2,137	67 out of 2,137 to receive 200 Shares	0.01%
140,000	4,941	175 out of 4,941 to receive 200 Shares	0.01%
<b>244,283</b>		Total number of Pool A successful applicants: 4,400	

NO. OF SHARES APPLIED FOR	NO. OF VALID APPLICATIONS	BASIS OF ALLOTMENT/BALLOT	APPROXIMATE PERCENTAGE ALLOTTED OF THE TOTAL NO. OF SHARES APPLIED FOR
<b>POOL B</b>			
160,000	3,804	786 out of 3,804 to receive 200 Shares	0.03%
180,000	1,398	289 out of 1,398 to receive 200 Shares	0.02%
200,000	2,479	514 out of 2,479 to receive 200 Shares	0.02%
250,000	1,866	387 out of 1,866 to receive 200 Shares	0.02%
300,000	1,617	336 out of 1,617 to receive 200 Shares	0.01%
350,000	1,139	237 out of 1,139 to receive 200 Shares	0.01%
400,000	1,026	214 out of 1,026 to receive 200 Shares	0.01%
450,000	779	163 out of 779 to receive 200 Shares	0.01%
500,000	1,145	242 out of 1,145 to receive 200 Shares	0.01%
600,000	964	205 out of 964 to receive 200 Shares	0.01%
700,000	581	124 out of 581 to receive 200 Shares	0.01%
800,000	409	88 out of 409 to receive 200 Shares	0.01%
879,800	3,698	814 out of 3,698 to receive 200 Shares	0.01%
<u>20,905</u>		Total number of Pool B successful applicants: 4,399	

*As of the date of this announcement, the relevant subscription monies previously deposited in the designated nominee accounts have been remitted back to the accounts of all HKSCC participants. Investors should contact their relevant brokers for any inquiries.*

### **COMPLIANCE WITH LISTING RULES AND GUIDANCE**

The Directors confirm that, except for the Listing Rules that have been waived and/or in respect of which consent has been obtained, the Company has complied with the Listing Rules and guidance materials in relation to the placing, allotment and listing of the Company's shares.

The Directors confirm that, to the best of their knowledge, no rebate has been, directly or indirectly, provided by the issuer, its controlling shareholder(s), directors or syndicate members to any placees or the public (as the case may be) and the consideration payable by them for each share (or, where applicable, each unit of other equity securities or interests (which include equity securities, interests in a REIT, stapled securities and securities of an investment company (as defined in Rule 21.01 of the Listing Rules)) of the issuer subscribed for or purchased by them is the same as the final offer price determined by the issuer, in addition to any brokerage, AFRC transaction levy, SFC transaction levy and trading fee payable.

## DISCLAIMERS

*Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) and Hong Kong Securities Clearing Company Limited (“HKSCC”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”). The securities may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the U.S. Securities Act and in compliance with any applicable state securities laws, or outside the United States unless in compliance with Regulation S under the U.S. Securities Act. There will be no public offer of securities in the United States.*

*The Offer Shares are being offered and sold outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act.*

*This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities. This announcement is not a prospectus. Potential investors should read the Prospectus dated October 28, 2025 issued by Vigonvita Life Sciences Co., Ltd. for detailed information about the Global Offering described below before deciding whether or not to invest in the Shares thereby being offered.*

*\* Potential investors of the Offer Shares should note that the Sole Sponsor and the Sponsor-Overall Coordinator (for itself and on behalf of the Hong Kong Underwriters) are entitled to terminate their obligations under the Hong Kong Underwriting Agreement with immediate effect upon the occurrence of any of the events set out in the paragraph headed “Underwriting – Underwriting Arrangements and Expenses – Hong Kong Public Offering – Grounds for Termination” in the Prospectus at any time prior to 8:00 a.m. (Hong Kong time) on the Listing Date (which is currently expected to be on November 6, 2025).*

## **PUBLIC FLOAT AND FREE FLOAT**

Immediately following the completion of the Global Offering, 51,149,722 H Shares, representing approximately 30.52% of our issued share capital (before any exercise of the Over-allotment Option) will count towards the public float. Therefore, we will satisfy Rule 19A.13A(1) of the Listing Rules, which requires the number of H Shares held by the public at the time of listing be at least 25% of the total number of shares in the class to which H Shares belong. Based on the Offer Price of HK\$33.37 per H Share, the Company satisfies the free float requirement under Rule 19A.13C(1) of the Listing Rules.

The Directors confirm that, immediately following completion of the Global Offering: (i) the Shares will be held by at least 300 Shareholders at the time of Listing, in compliance with Rule 8.08(2) of the Listing Rules; (ii) the three largest public Shareholders will not hold more than 50% of the H Shares held in public hands at the time of Listing, in compliance with Rules 8.08(3) and 8.24 of the Listing Rules; (iii) no placee will, individually, be placed more than 10% of the enlarged issued share capital of the Company immediately after the Global Offering; and (iv) there will not be any new substantial Shareholder (as defined in the Listing Rules) immediately after the Global Offering.

## **COMMENCEMENT OF DEALINGS**

The H Share certificates will only become valid evidence of title at 8:00 a.m. on Thursday, November 6, 2025 (Hong Kong time), provided that the Global Offering has become unconditional in all respects and the right of termination described in “Underwriting – Underwriting Arrangements and Expenses – Hong Kong Public Offering – Grounds for Termination” has not been exercised. Investors who trade H Shares prior to the receipt of H Share certificates or prior to the H Share certificates becoming valid evidence of title do so entirely at their own risk.

Assuming that the Hong Kong Public Offering becomes unconditional at or before 8:00 a.m. in Hong Kong on Thursday, November 6, 2025, it is expected that dealings in the H Shares on the Stock Exchange will commence at 9:00 a.m. on Thursday, November 6, 2025.

The H Shares will be traded in board lots of 200 H Shares each and the stock code of the H Shares will be 2630.

By order of the Board  
**Vigonvita Life Sciences Co., Ltd.**  
**Dr. Tian Guanghui**  
*Chairman of the Board, Executive Director,  
Chief Executive Officer and General Manager*

Hong Kong, November 5, 2025

*As of the date of this announcement, the Board comprises Dr. Tian Guanghui and Dr. Hu Tianwen as executive directors, Mr. Liu Haoxuan as non-executive director, and Dr. Ju Dianwen, Ms. Cao Xinwen and Dr. Xu Hongxi as independent non-executive directors.*